Jule Pinter, David J Tunnicliffe, Pooshwikaa Karunikaikumar, Anastasios Anastasiadis, Robert K Hills
{"title":"肾衰竭治疗效果估计目标试验方法回顾:系统评估协议。","authors":"Jule Pinter, David J Tunnicliffe, Pooshwikaa Karunikaikumar, Anastasios Anastasiadis, Robert K Hills","doi":"10.1186/s13643-024-02672-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patients with kidney failure often lack robust evidence because they are excluded from randomized trials. Trial emulation provides an alternative approach to derive treatment effect estimates when randomized trials cannot be conducted. Critical questions about the comparative efficacy and safety of interventions in kidney failure are now being answered using this approach or parts of it. However, variations and inconsistencies in reporting cast doubt on the reliability and validity of effect estimates not derived from randomized trials. The aim of this methodological systematic review is to understand the extent to which the target study approach is used in kidney failure and the appropriateness of this approach. By identifying and evaluating studies that qualify as emulating a target trial, compared with studies that did not apply the principles. We aim to provide more specific methodological guidance to increase the clarity and reliability of reporting treatment effect estimates when running a trial in kidney failure is not feasible.</p><p><strong>Methods: </strong>This protocol is developed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) statement. MEDLINE, Embase, and reference lists (backwards citation chasing) will be searched up until 1st July 2023 and the search updated prior to publication to identify all studies evaluating patient outcomes in late-stage kidney disease and failure that use target trial emulation as the primary approach for analysis. Two authors (A. A., P. K.) will select articles based on title and abstract and then full text, with a third reviewer settling disagreements (J. P.). The prespecified variables will be extracted, and the risk of bias will be assessed by at least two authors (A. A., P. K., A. N.) using prespecified data forms. This will enable the determination of the robustness of the methodological quality of observational studies in using the whole or elements of the target trial approach. We will thereby assess their ability to reliably report treatment effect estimates.</p><p><strong>Discussion: </strong>We will provide specific methodological recommendations on how to design target trials and model assumptions for emulation to get reliable treatment effect estimates for therapeutic interventions in kidney failure.</p><p><strong>Methodological systematic review registration: </strong>Open Science Framework: Identifier https://doi.org/10.17605/OSF.IO/Z4Y29 .</p>","PeriodicalId":22162,"journal":{"name":"Systematic Reviews","volume":"13 1","pages":"280"},"PeriodicalIF":6.3000,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566441/pdf/","citationCount":"0","resultStr":"{\"title\":\"Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.\",\"authors\":\"Jule Pinter, David J Tunnicliffe, Pooshwikaa Karunikaikumar, Anastasios Anastasiadis, Robert K Hills\",\"doi\":\"10.1186/s13643-024-02672-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Patients with kidney failure often lack robust evidence because they are excluded from randomized trials. Trial emulation provides an alternative approach to derive treatment effect estimates when randomized trials cannot be conducted. Critical questions about the comparative efficacy and safety of interventions in kidney failure are now being answered using this approach or parts of it. However, variations and inconsistencies in reporting cast doubt on the reliability and validity of effect estimates not derived from randomized trials. The aim of this methodological systematic review is to understand the extent to which the target study approach is used in kidney failure and the appropriateness of this approach. By identifying and evaluating studies that qualify as emulating a target trial, compared with studies that did not apply the principles. We aim to provide more specific methodological guidance to increase the clarity and reliability of reporting treatment effect estimates when running a trial in kidney failure is not feasible.</p><p><strong>Methods: </strong>This protocol is developed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) statement. MEDLINE, Embase, and reference lists (backwards citation chasing) will be searched up until 1st July 2023 and the search updated prior to publication to identify all studies evaluating patient outcomes in late-stage kidney disease and failure that use target trial emulation as the primary approach for analysis. Two authors (A. A., P. K.) will select articles based on title and abstract and then full text, with a third reviewer settling disagreements (J. P.). The prespecified variables will be extracted, and the risk of bias will be assessed by at least two authors (A. A., P. K., A. N.) using prespecified data forms. This will enable the determination of the robustness of the methodological quality of observational studies in using the whole or elements of the target trial approach. We will thereby assess their ability to reliably report treatment effect estimates.</p><p><strong>Discussion: </strong>We will provide specific methodological recommendations on how to design target trials and model assumptions for emulation to get reliable treatment effect estimates for therapeutic interventions in kidney failure.</p><p><strong>Methodological systematic review registration: </strong>Open Science Framework: Identifier https://doi.org/10.17605/OSF.IO/Z4Y29 .</p>\",\"PeriodicalId\":22162,\"journal\":{\"name\":\"Systematic Reviews\",\"volume\":\"13 1\",\"pages\":\"280\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11566441/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Systematic Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13643-024-02672-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13643-024-02672-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:肾衰竭患者往往被排除在随机试验之外,因此缺乏有力的证据。在无法进行随机试验的情况下,试验仿真为得出治疗效果估计值提供了另一种方法。目前,有关肾衰竭干预措施的比较疗效和安全性的关键问题正在通过这种方法或部分方法得到解答。然而,报告中的差异和不一致性使人们对非随机试验得出的疗效估计值的可靠性和有效性产生了怀疑。本方法学系统综述旨在了解目标研究法在肾衰竭中的应用程度以及该方法的适宜性。通过识别和评估符合目标试验条件的研究,并与未采用目标试验原则的研究进行比较。我们旨在提供更具体的方法学指导,以提高在肾衰竭中进行试验不可行时报告治疗效果估计值的清晰度和可靠性:方法:本方案根据系统综述和荟萃分析首选报告项目(PRISMA-P)声明制定。我们将检索MEDLINE、Embase和参考文献列表(反向引用追溯),直至2023年7月1日,并在发表前更新检索结果,以确定所有评估晚期肾病和肾衰竭患者预后的研究,这些研究以目标试验模拟作为主要分析方法。两位作者(A. A. 和 P. K.)将根据标题和摘要选择文章,然后再选择全文,由第三位审稿人(J. P.)解决分歧。至少两名作者(A. A.、P. K.、A. N.)将使用预先指定的数据表格提取预先指定的变量并评估偏倚风险。这将有助于确定观察性研究在使用目标试验方法的全部或部分内容时方法质量的稳健性。因此,我们将评估这些研究可靠地报告治疗效果估计值的能力:我们将就如何设计目标试验和模型假设提供具体的方法学建议,以便为肾衰竭的治疗干预获得可靠的治疗效果估计值:开放科学框架:标识符 https://doi.org/10.17605/OSF.IO/Z4Y29 。
Review of the target trial methodological approach on treatment effect estimates in kidney failure: protocol for a systematic assessment.
Background: Patients with kidney failure often lack robust evidence because they are excluded from randomized trials. Trial emulation provides an alternative approach to derive treatment effect estimates when randomized trials cannot be conducted. Critical questions about the comparative efficacy and safety of interventions in kidney failure are now being answered using this approach or parts of it. However, variations and inconsistencies in reporting cast doubt on the reliability and validity of effect estimates not derived from randomized trials. The aim of this methodological systematic review is to understand the extent to which the target study approach is used in kidney failure and the appropriateness of this approach. By identifying and evaluating studies that qualify as emulating a target trial, compared with studies that did not apply the principles. We aim to provide more specific methodological guidance to increase the clarity and reliability of reporting treatment effect estimates when running a trial in kidney failure is not feasible.
Methods: This protocol is developed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocols (PRISMA-P) statement. MEDLINE, Embase, and reference lists (backwards citation chasing) will be searched up until 1st July 2023 and the search updated prior to publication to identify all studies evaluating patient outcomes in late-stage kidney disease and failure that use target trial emulation as the primary approach for analysis. Two authors (A. A., P. K.) will select articles based on title and abstract and then full text, with a third reviewer settling disagreements (J. P.). The prespecified variables will be extracted, and the risk of bias will be assessed by at least two authors (A. A., P. K., A. N.) using prespecified data forms. This will enable the determination of the robustness of the methodological quality of observational studies in using the whole or elements of the target trial approach. We will thereby assess their ability to reliably report treatment effect estimates.
Discussion: We will provide specific methodological recommendations on how to design target trials and model assumptions for emulation to get reliable treatment effect estimates for therapeutic interventions in kidney failure.
Methodological systematic review registration: Open Science Framework: Identifier https://doi.org/10.17605/OSF.IO/Z4Y29 .
期刊介绍:
Systematic Reviews encompasses all aspects of the design, conduct and reporting of systematic reviews. The journal publishes high quality systematic review products including systematic review protocols, systematic reviews related to a very broad definition of health, rapid reviews, updates of already completed systematic reviews, and methods research related to the science of systematic reviews, such as decision modelling. At this time Systematic Reviews does not accept reviews of in vitro studies. The journal also aims to ensure that the results of all well-conducted systematic reviews are published, regardless of their outcome.